Key result
Transcatheter tricuspid repair successfully treats severe biopsy-related TR in a high-risk transplant recipient at 3 months.
Why the study?
Can percutaneous transcatheter tricuspid repair effectively treat severe tricuspid regurgitation in a high-risk patient after heart transplantation?
Can percutaneous transcatheter tricuspid repair effectively treat severe tricuspid regurgitation in a high-risk patient after heart transplantation?
Transcatheter tricuspid repair is a feasible percutaneous option for treating severe tricuspid regurgitation caused by biopsy-related chordal rupture in high-risk heart transplant recipients.
May offer a percutaneous option in high-risk post-transplant TR; leaves open durability and generalizability pending prospective data.
A 67-year-old patient with history of heart transplantation was referred for symptomatic severe tricuspid regurgitation. Diagnostic workup showed chordal ruptures on the septal and anterior leaflets, most likely related to endomyocardial biopsies. Given the high surgical risk, the patient was treated percutaneously, with good results persisting at 3 months. (Level of Difficulty: Intermediate.)
No takes yet. Share an insight, caveat, or question.
Puscas et al. (2023) studied this question. Transcatheter tricuspid repair successfully treated severe biopsy-related tricuspid regurgitation in a high-risk heart transplant recipient, with good results persisting at 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: